bluebird bio (BLUE) Valuation Upside is Incremental Says Maxim, Remains Sidelined
Tweet Send to a Friend
Maxim Group maintains Hold on bluebird bio (NASDAQ: BLUE) price target of $200.00.Analyst Jason McCarthy comments "blue's gene therapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
